TY - JOUR
T1 - Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations from the European Hematology Association and the European LeukemiaNet
AU - Itzykson, Raphael
AU - Fenaux, Pierre
AU - Bowen, David
AU - Cross, Nicholas C. P.
AU - Cortes, Jorge
AU - de Witte, Theo
AU - Germing, Ulrich
AU - Onida, Francesco
AU - Padron, Eric
AU - Platzbecker, Uwe
AU - Santini, Valeria
AU - Sanz, Guillermo F.
AU - Solary, Eric
AU - van de Loosdrecht, Arjan
AU - Malcovati, Luca
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Chronic myelomonocytic leukemia (CMML) is a disease of the elderly, and by far the most frequent overlap myelodysplastic/myeloproliferative neoplasm in adults. Aside from the chronic monocytosis that remains the cornerstone of its diagnosis, the clinical presentation of CMML includes dysplastic features, cytopenias, excess of blasts, or myeloproliferative features including high white blood cell count or splenomegaly. Prognosis is variable, with several prognostic scoring systems reported in recent years, and treatment is poorly defined, with options ranging from watchful waiting to allogeneic stem cell transplantation, which remains the only curative therapy for CMML. Here, we present on behalf of the European Hematology Association and the European LeukemiaNet, evidence-and consensus-based guidelines, established by an international group of experts, from Europe and the United States, for standardized diagnostic and prognostic procedures and for an appropriate choice of therapeutic interventions in adult patients with CMML.
AB - Chronic myelomonocytic leukemia (CMML) is a disease of the elderly, and by far the most frequent overlap myelodysplastic/myeloproliferative neoplasm in adults. Aside from the chronic monocytosis that remains the cornerstone of its diagnosis, the clinical presentation of CMML includes dysplastic features, cytopenias, excess of blasts, or myeloproliferative features including high white blood cell count or splenomegaly. Prognosis is variable, with several prognostic scoring systems reported in recent years, and treatment is poorly defined, with options ranging from watchful waiting to allogeneic stem cell transplantation, which remains the only curative therapy for CMML. Here, we present on behalf of the European Hematology Association and the European LeukemiaNet, evidence-and consensus-based guidelines, established by an international group of experts, from Europe and the United States, for standardized diagnostic and prognostic procedures and for an appropriate choice of therapeutic interventions in adult patients with CMML.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85069961085&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/31723789
U2 - https://doi.org/10.1097/HS9.0000000000000150
DO - https://doi.org/10.1097/HS9.0000000000000150
M3 - Article
C2 - 31723789
SN - 2572-9241
VL - 2
JO - HemaSphere
JF - HemaSphere
IS - 6
M1 - e150
ER -